Anton G.T. Terwisscha van Scheltinga

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Laetitia E. Lamberts, Maximillian Koch, Johannes S. de Jong et al. · Clinical Cancer Research · 2016 · 285 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies

Anton G.T. Terwisscha van Scheltinga, Gooitzen M. van Dam, Wouter B. Nagengast et al. · Journal of Nuclear Medicine · 2011 · 202 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting et al. · Cancer Research · 2013 · 120 citations · Full text

Medicine, Cancer Biology, Oncology +17

First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma

Kim S. de Valk, Marion M. Deken, Henricus J.M. Handgraaf et al. · Clinical Cancer Research · 2020 · 109 citations

Medicine, Oncology, Biomedical Imaging +16

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Frederike Bensch, Laetitia E. Lamberts, Michaël M. Smeenk et al. · Clinical Cancer Research · 2017 · 70 citations · Full text

Medicine, Nuclear Medicine, Oncology +17